Logo image of VERU

VERU INC (VERU) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VERU - US92536C2026 - Common Stock

2.59 USD
+0.04 (+1.57%)
Last: 1/21/2026, 8:00:03 PM
2.61 USD
+0.02 (+0.77%)
After Hours: 1/21/2026, 8:00:03 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VERU. VERU was compared to 191 industry peers in the Pharmaceuticals industry. While VERU seems to be doing ok healthwise, there are quite some concerns on its profitability. VERU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • VERU had negative earnings in the past year.
  • VERU had a negative operating cash flow in the past year.
  • VERU had negative earnings in 4 of the past 5 years.
  • In the past 5 years VERU always reported negative operating cash flow.
VERU Yearly Net Income VS EBIT VS OCF VS FCFVERU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M

1.2 Ratios

  • VERU has a worse Return On Assets (-76.17%) than 73.30% of its industry peers.
  • The Return On Equity of VERU (-123.97%) is worse than 65.44% of its industry peers.
Industry RankSector Rank
ROA -76.17%
ROE -123.97%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
VERU Yearly ROA, ROE, ROICVERU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • VERU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERU Yearly Profit, Operating, Gross MarginsVERU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

  • VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VERU remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, VERU has more shares outstanding
  • There is no outstanding debt for VERU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VERU Yearly Shares OutstandingVERU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
VERU Yearly Total Debt VS Total AssetsVERU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -16.42, we must say that VERU is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -16.42, VERU is not doing good in the industry: 80.63% of the companies in the same industry are doing better.
  • VERU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.42
ROIC/WACCN/A
WACC9.49%
VERU Yearly LT Debt VS Equity VS FCFVERU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • VERU has a Current Ratio of 2.43. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
  • VERU's Current ratio of 2.43 is in line compared to the rest of the industry. VERU outperforms 45.03% of its industry peers.
  • VERU has a Quick Ratio of 2.43. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
  • VERU has a Quick ratio (2.43) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.43
VERU Yearly Current Assets VS Current LiabilitesVERU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 46.43% over the past year.
  • The Revenue for VERU has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)46.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.67% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.36%
EPS Next 2Y5%
EPS Next 3Y18.24%
EPS Next 5Y3.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VERU Yearly Revenue VS EstimatesVERU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2032 2033 20M 40M 60M 80M 100M
VERU Yearly EPS VS EstimatesVERU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • VERU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VERU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERU Price Earnings VS Forward Price EarningsVERU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERU Per share dataVERU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • VERU's earnings are expected to grow with 18.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5%
EPS Next 3Y18.24%

More info and screens

0

5. Dividend

5.1 Amount

  • VERU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

VERU INC

NASDAQ:VERU (1/21/2026, 8:00:03 PM)

After market: 2.61 +0.02 (+0.77%)

2.59

+0.04 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-17
Earnings (Next)02-11
Inst Owners22.05%
Inst Owner Change-30.57%
Ins Owners9.78%
Ins Owner Change0%
Market Cap37.97M
Revenue(TTM)N/A
Net Income(TTM)-22.73M
Analysts82
Price Target22.95 (786.1%)
Short Float %4.71%
Short Ratio3.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)65.58%
Min EPS beat(2)8.08%
Max EPS beat(2)123.07%
EPS beat(4)4
Avg EPS beat(4)43.01%
Min EPS beat(4)8.08%
Max EPS beat(4)123.07%
EPS beat(8)6
Avg EPS beat(8)21.21%
EPS beat(12)8
Avg EPS beat(12)16.35%
EPS beat(16)9
Avg EPS beat(16)4.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.88%
PT rev (3m)5.88%
EPS NQ rev (1m)8.85%
EPS NQ rev (3m)8.85%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 3.32
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS1.25
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.17%
ROE -123.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.02%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.43
Altman-Z -16.42
F-Score3
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)217.76%
Cap/Depr(5y)171.53%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y-20.36%
EPS Next 2Y5%
EPS Next 3Y18.24%
EPS Next 5Y3.67%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.36%
OCF growth 3YN/A
OCF growth 5YN/A

VERU INC / VERU FAQ

Can you provide the ChartMill fundamental rating for VERU INC?

ChartMill assigns a fundamental rating of 2 / 10 to VERU.


Can you provide the valuation status for VERU INC?

ChartMill assigns a valuation rating of 0 / 10 to VERU INC (VERU). This can be considered as Overvalued.


What is the profitability of VERU stock?

VERU INC (VERU) has a profitability rating of 0 / 10.


Can you provide the financial health for VERU stock?

The financial health rating of VERU INC (VERU) is 6 / 10.